MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock News

Canada - Toronto Stock Exchange - TSX:MDP - CA58410Q2036 - Common Stock

2.74 CAD

+0.06 (+2.24%)

Last: 12/4/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

MDP.CA Latest News, Press Relases and Analysis

All

Press Releases

10 months ago - By: Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares

10 months ago - By: Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares

a year ago - By: Invezz

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

a year ago - By: Invezz

Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date

2 years ago - By: Medexus Pharmaceuticals, Inc.

Medexus Pharmaceuticals Announces C$10 Million Bought-Deal Public Offering of Units

3 years ago - By: Seeking Alpha

Medexus gets TSX nod to make NCIB for convertible debentures (TSX:MDP:CA)

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Expects Record Revenue for Fiscal Year 2023 and Provides Business Update

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Announces New License Deal for Topical Terbinafine

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Announces US$58.5 million in New Credit Facilities

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Welcomes Two New Board Members

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Secures Public Reimbursement for Cuvposa® in Quebec

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Schedules Third Fiscal Quarter 2023 Conference Call

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Expects Record Revenue for Fiscal Q3 2023 and Provides Business Update

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Schedules Second Quarter 2023 Conference Call

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus and MidCap Agree to Increase in MidCap’s Revolving Loan Commitment Amount

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Holds Annual Meeting of Shareholders and Announces Election of Board of Directors

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Schedules First Quarter 2023 Conference Call

3 years ago - By: Medexus Pharmaceuticals Inc

Treosulfan NDA Resubmitted to FDA

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

3 years ago - By: Medexus Pharmaceuticals Inc

Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

4 years ago - By: Medexus Pharmaceuticals Inc

Treosulfan Pivotal Study Results Published